Literature DB >> 11598034

Critical role for tumor necrosis factor alpha in controlling the number of lumenal pathogenic bacteria and immunopathology in infectious colitis.

N S Gonçalves1, M Ghaem-Maghami, G Monteleone, G Frankel, G Dougan, D J Lewis, C P Simmons, T T MacDonald.   

Abstract

Infection of mice with the intestinal bacterial pathogen Citrobacter rodentium results in colonic mucosal hyperplasia and a local Th1 inflammatory response similar to that seen in mouse models of inflammatory bowel disease. In these latter models, and in patients with Crohn's disease, neutralization of tumor necrosis factor alpha (TNF-alpha) is of therapeutic benefit. Since there is no information on the role of TNF-alpha in either immunity to noninvasive bacterial pathogens or on the role of TNF-alpha in the immunopathology of infectious colitis, we investigated C. rodentium infection in TNFRp55(-/-) mice. In TNFRp55(-/-) mice, there were higher colonic bacterial burdens, but the organisms were cleared at the same rate as C57BL/6 mice, showing that TNF-alpha is not needed for protective antibacterial immunity. The most striking feature of infection in TNFRp55(-/-) mice, however, was the markedly enhanced pathology, with increased mucosal weight and thickness, increased T-cell infiltrate, and a markedly greater mucosal Th1 response. Interleukin-12 p40 transcripts were markedly elevated in C. rodentium-infected TNFRp55(-/-) mice, and this was associated with enhanced mucosal STAT4 phosphorylation. TNF-alpha is not obligatory for protective immunity to C. rodentium in mice; however, it appears to play some role in downregulating mucosal pathology and Th1 immune responses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11598034      PMCID: PMC100039          DOI: 10.1128/IAI.69.11.6651-6659.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  59 in total

1.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Authors:  S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts
Journal:  N Engl J Med       Date:  1997-10-09       Impact factor: 91.245

2.  A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production.

Authors:  S L Pender; J M Fell; S M Chamow; A Ashkenazi; T T MacDonald
Journal:  J Immunol       Date:  1998-04-15       Impact factor: 5.422

Review 3.  The central role of chemokines (chemotactic cytokines) in the immunopathogenesis of ulcerative colitis and Crohn's disease.

Authors:  R P MacDermott; I R Sanderson; H C Reinecker
Journal:  Inflamm Bowel Dis       Date:  1998-02       Impact factor: 5.325

4.  Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies.

Authors:  D Kontoyiannis; M Pasparakis; T T Pizarro; F Cominelli; G Kollias
Journal:  Immunity       Date:  1999-03       Impact factor: 31.745

5.  Citrobacter rodentium infection in mice elicits a mucosal Th1 cytokine response and lesions similar to those in murine inflammatory bowel disease.

Authors:  L M Higgins; G Frankel; G Douce; G Dougan; T T MacDonald
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

6.  TNF-alpha, nitric oxide and IFN-gamma are all critical for development of necrosis in the small intestine and early mortality in genetically susceptible mice infected perorally with Toxoplasma gondii.

Authors:  O Liesenfeld; H Kang; D Park; T A Nguyen; C V Parkhe; H Watanabe; T Abo; A Sher; J S Remington; Y Suzuki
Journal:  Parasite Immunol       Date:  1999-07       Impact factor: 2.280

7.  Interactions between stromal cell--derived keratinocyte growth factor and epithelial transforming growth factor in immune-mediated crypt cell hyperplasia.

Authors:  M Bajaj-Elliott; R Poulsom; S L Pender; N C Wathen; T T MacDonald
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

8.  Inhibition of interferon gamma induced interleukin 12 production: a potential mechanism for the anti-inflammatory activities of tumor necrosis factor.

Authors:  J Hodge-Dufour; M W Marino; M R Horton; A Jungbluth; M D Burdick; R M Strieter; P W Noble; C A Hunter; E Puré
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

9.  The regulation and functional consequence of proinflammatory cytokine binding on human intestinal epithelial cells.

Authors:  A Panja; S Goldberg; L Eckmann; P Krishen; L Mayer
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422

10.  Detection of intimins alpha, beta, gamma, and delta, four intimin derivatives expressed by attaching and effacing microbial pathogens.

Authors:  J Adu-Bobie; G Frankel; C Bain; A G Goncalves; L R Trabulsi; G Douce; S Knutton; G Dougan
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

View more
  49 in total

1.  The role of Gr-1(+) cells and tumour necrosis factor-α signalling during Clostridium difficile colitis in mice.

Authors:  Andrew J McDermott; Kathryn E Higdon; Ryan Muraglia; John R Erb-Downward; Nicole R Falkowski; Roderick A McDonald; Vincent B Young; Gary B Huffnagle
Journal:  Immunology       Date:  2015-04       Impact factor: 7.397

2.  Concurrent infection with an intestinal helminth parasite impairs host resistance to enteric Citrobacter rodentium and enhances Citrobacter-induced colitis in mice.

Authors:  Chien-Chang Chen; Steve Louie; Beth McCormick; W Allan Walker; Hai Ning Shi
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Role of EspA and intimin in expression of proinflammatory cytokines from enterocytes and lymphocytes by rabbit enteropathogenic Escherichia coli-infected rabbits.

Authors:  Karina Ramirez; Rocio Huerta; Eric Oswald; Carlos Garcia-Tovar; Jose Manuel Hernandez; Fernando Navarro-Garcia
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  Toll-like receptor 4 contributes to colitis development but not to host defense during Citrobacter rodentium infection in mice.

Authors:  Mohammed A Khan; Caixia Ma; Leigh A Knodler; Yanet Valdez; Carrie M Rosenberger; Wanyin Deng; B Brett Finlay; Bruce A Vallance
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

5.  CD4+-T-cell effector functions and costimulatory requirements essential for surviving mucosal infection with Citrobacter rodentium.

Authors:  Lynn Bry; Manfred Brigl; Michael B Brenner
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

6.  Helminth-primed dendritic cells alter the host response to enteric bacterial infection.

Authors:  Chien-Chang Chen; Steve Louie; Beth A McCormick; W Allan Walker; Hai Ning Shi
Journal:  J Immunol       Date:  2006-01-01       Impact factor: 5.422

7.  Alternatively activated macrophages in intestinal helminth infection: effects on concurrent bacterial colitis.

Authors:  Meiqian Weng; Deke Huntley; I-Fei Huang; Ondulla Foye-Jackson; Lijian Wang; Aliese Sarkissian; Qingping Zhou; W Allan Walker; Bobby J Cherayil; Hai Ning Shi
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

8.  Development of fatal colitis in FVB mice infected with Citrobacter rodentium.

Authors:  Diana Borenshtein; Prashant R Nambiar; Elizabeth B Groff; James G Fox; David B Schauer
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

9.  IL-6-dependent mucosal protection prevents establishment of a microbial niche for attaching/effacing lesion-forming enteric bacterial pathogens.

Authors:  Sara M Dann; Martina E Spehlmann; Dustin C Hammond; Mitsutoshi Iimura; Koji Hase; Lillian J Choi; Elaine Hanson; Lars Eckmann
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

10.  Central role for B lymphocytes and CD4+ T cells in immunity to infection by the attaching and effacing pathogen Citrobacter rodentium.

Authors:  Cameron P Simmons; Simon Clare; Marjan Ghaem-Maghami; Tania K Uren; Joanna Rankin; Allan Huett; Rob Goldin; David J Lewis; Thomas T MacDonald; Richard A Strugnell; Gad Frankel; Gordon Dougan
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.